Prevalence and Clinical Significance of FLT3 Mutation Status in Acute Myeloid Leukemia Patients: A Multicenter Study

Background: The prognostic significance of miR-125b in intermediate-risk acute myeloid leukemia has not been well investigated. The aim of the study was to reveal the relationship between the elevated exosomal miR-125b level and the poor prognosis in adult patients with this disease. Methods: A total of 154 consecutive patients with intermediate-risk acute myeloid leukemia were enrolled. Exosomes were isolated from blood specimens. The exosomal miR-125b level was determined using quantitative real-time polymerase chain reaction. Patients received standardized therapy and were followed up for 1–24 months. Details about relapse and overall death were recorded. Results: Patients were divided into the high miR-125b level group (n = 77) and the low miR-125b level group (n = 77). In the multivariate Cox proportional hazard regression model, the high miR-125b level group was separately associated with increased risks of relapse and overall death in 2 years (hazard ratio [HR] 2.84, 95% CI 1.81–4.33 and HR 2.69, 95% CI 1.87–4.52). Kaplan-Meier analysis also revealed that a high miR-125b level was related to a higher cumulative relapse and overall death rates (p < 0.001 and p < 0.001, respectively). Conclusion: Circulating exosomal miR-125b concentration might be an independent prognostic indicator in intermediate-risk acute myeloid leukemia patients. An elevated miR-125b level indicated higher risks of relapse and overall death.

show abstract

“…FLT3 mutation, MLL mutation, and more than one course to CR were recognized as adverse conditions for AML prognosis [26,27]. As shown in …”

Section: Resultsmentioning

confidence: 96%

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The prevalence of FLT3 mutation seems to be lower in adult AML Hispanic patients than in other groups, although technical limitations may have contributed to the observed differences (22). Ruiz Arguelles et al reported 13% in 31 patients, while Arana Trejo et al found 15% of FLT3 mutated in 21 patients; both studies were done in Mexican patients (11). A collaborative study, including patients from referral centers in Mexico and Colombia, reported only 20% of FLT3 POS patients.…”

Section: Discussionmentioning

confidence: 96%

“…A collaborative study, including patients from referral centers in Mexico and Colombia, reported only 20% of FLT3 POS patients. They analyzed 138 patients with de novo or secondary AML (11). This study also included the patients previously reported by Arana Trejo and Ruiz Arguelles (11).…”

Section: Discussionmentioning

confidence: 99%

“…They analyzed 138 patients with de novo or secondary AML (11). This study also included the patients previously reported by Arana Trejo and Ruiz Arguelles (11). In AML adults from Argentina, Sánchez et al (25) reported 20.6%, while in Brazil, 26.3% was found (26).…”

Section: Discussionmentioning

confidence: 99%

“…Epidemiological data about the FLT3 mutational profile and its clinical impact in Mexican AML patients are minimal. Studies including a small number of de novo and secondary AML patients (children and adults) have reported a prevalence between 13 and 20% of FLT3 mutation using polymerase chain reaction (PCR)-based technologies (11).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Profiling FLT3 Mutations in Mexican Acute Myeloid Leukemia Pediatric Patients: Impact on Overall Survival

et al. 2020

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is the second most frequent leukemia in childhood. The FLT3 gene participates in hematopoietic stem cell proliferation. FLT3 mutations are recurrent in AML and influence prognosis. In Mexican pediatric AML patients, FLT3 mutational profile, and their clinical impact have not been evaluated. Aim of the study: This study aimed to identify the profile of FLT3 mutations in pediatric patients with de novo AML and to assess their possible influence on overall survival (OS) and other clinical features. Methods: Massive parallel target sequencing of FLT3 was performed in 80 patients. Results: FLT3 mutations [internal tandem duplication (ITD) or tyrosine kinase domain (TKD)] were identified in 24% of them. OS was significantly lower in FLT3 POS cases than in FLT3 NEG (p = 0.03). The average OS for FLT3 POS was 1.2 vs. 2.2 years in FLT3 NEG. There were no significant differences in the children's sex, age, percentage of blasts in Molina Garay et al. FLT3 in Mexican AML Pediatric Patients bone marrow aspirate, or white blood cell count in peripheral blood at diagnosis between both groups. No differences were identified stratifying by the mutational load (high > 0.4) or type of mutation. The negative effect of FLT3 mutations was also observed in patients with acute promyelocytic leukemia (APL). Conclusions: FLT3 mutational profile is described in Mexican pediatric AML patients for the first time. Mutated FLT3 negatively impacts the outcome of AML patients, even considering the APL group. The clinical benefit from treatment with tyrosine kinase inhibitors in the FLT3 POS pediatric patients needs to be assessed in clinical trials. FLT3 testing may contribute to better risk stratification in our pediatric AML patients.

show abstract

Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis

Solís-Armenta,

Rodríguez-Rodríguez,

Hernández-Pérez

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Prevalence and Clinical Significance of FLT3 Mutation Status in Acute Myeloid Leukemia Patients: A Multicenter Study

Cited by 15 publications

References 35 publications

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia

Profiling FLT3 Mutations in Mexican Acute Myeloid Leukemia Pediatric Patients: Impact on Overall Survival

Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis

Contact Info

Product

Resources

About